Understanding New Ways to Fight Triple Negative Breast Cancer
Mechanistic Evaluation of Macrocyclic Diterpenoids with Selective Triple Negative Breast Cancer Activity
This project looks for new ways to treat triple-negative breast cancer, especially for patients who don't respond well to current chemotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of the Incarnate Word NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11193439 on NIH RePORTER |
What this research studies
Triple-negative breast cancer (TNBC) is a challenging disease because it lacks common targets for therapy, making chemotherapy the main treatment. Many patients find that chemotherapy alone isn't enough, especially in later stages. Our project explores natural compounds, specifically yuanhuacine, to see if they can specifically target certain types of TNBC cells. We want to understand exactly how yuanhuacine works at a molecular level to kill these cancer cells, focusing on a specific protein pathway. This knowledge could help us develop more effective and targeted treatments for TNBC.
Who could benefit from this research
Good fit: This foundational research is focused on understanding disease mechanisms and is not currently recruiting patients for direct participation.
Not a fit: Patients whose breast cancer is not triple-negative would likely not benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to new, more targeted treatment options for patients with triple-negative breast cancer, especially those who don't respond to current chemotherapy.
How similar studies have performed: This project builds on preliminary findings that identified yuanhuacine as a potential agent, but its specific mechanisms of action are novel and currently being explored.
Where this research is happening
San Antonio, United States
- University of the Incarnate Word — San Antonio, United States (Active)
Researchers
- Principal investigator: Fermaintt, Charles Steven — University of the Incarnate Word
- Study coordinator: Fermaintt, Charles Steven
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.